Welcome to our dedicated page for Rani Therapeutics Holdings SEC filings (Ticker: RANI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rani Therapeutics Holdings, Inc. (RANI) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including Current Reports on Form 8-K and other key documents. These filings offer detailed information on material events affecting the clinical-stage biotherapeutics company, which focuses on oral delivery of biologics and drugs through its RaniPill® platform.
Rani’s recent Form 8-K filings have covered financial results and corporate updates, such as quarterly earnings releases where the company reports research and development expenses, general and administrative expenses, net loss figures and cash balances. These filings often incorporate press releases as exhibits, giving investors a structured view of the company’s operating performance and cash runway expectations.
Other 8-K filings document material agreements and capital markets transactions, including securities purchase agreements for private placements, registration rights agreements, amendments to loan and security agreements, and details of warrant issuances and debt conversions. Rani has also filed 8-Ks describing its Collaboration and License Agreement with Chugai Pharmaceutical Co., Ltd. and a collaboration with ProGen Co., Ltd., outlining upfront payments, milestone structures, royalty terms and shared development responsibilities for products that combine partner molecules with the RaniPill or RaniPill HC devices.
Filings further address governance and listing matters, such as notices from The Nasdaq Stock Market LLC regarding minimum bid price compliance, director appointments and resignations, and reconstitution of board committees. Through Stock Titan, users can review these filings alongside AI-powered summaries that highlight the main points of lengthy documents, helping to interpret complex sections on financing terms, collaboration structures and listing requirements without reading every line.
For investors researching RANI, this page is a central resource to examine 10-K and 10-Q reports when available, Form 8-K current reports and any future Form 4 insider transaction filings, with real-time updates from EDGAR and AI-generated explanations that clarify technical language and regulatory disclosures.
Rani Therapeutics (Nasdaq:RANI) filed an 8-K disclosing receipt of a Nasdaq minimum-bid-price deficiency notice. The stock closed below $1.00 for 30 consecutive business days, violating Listing Rule 5450(a)(1).
The Company has 180 days, until December 17 2025, to lift its bid to at least $1.00 for 10 straight sessions. If unsuccessful, Rani may seek a second 180-day grace period by moving to the Nasdaq Capital Market and, if needed, enacting a reverse stock split. Failure to regain compliance would result in delisting.
Management is monitoring the share price and evaluating alternatives but gives no assurance of success. Liquidity, investor base and valuation could be materially affected if the listing is lost.